Stem definition | Drug id | CAS RN |
---|---|---|
nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives | 480 | 154361-50-9 |
None
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
EoM (Fraction excreted unchanged in urine) | 3 % | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 26 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 171.93 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
Date | Agency | Company | Orphan |
---|---|---|---|
April 16, 2003 | PMDA | CHUGAI PHARMACEUTICAL CO., LTD. | |
April 30, 1998 | FDA | HOFFMANN LA ROCHE | |
Nov. 19, 2012 | EMA | medac Gesellschaft für klinische Spezialpräparate mbH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Palmar-plantar erythrodysaesthesia syndrome | 8018.66 | 13.54 | 2544 | 110902 | 20471 | 63355105 |
Disease progression | 3732.96 | 13.54 | 2462 | 110984 | 120296 | 63255280 |
Diarrhoea | 2558.45 | 13.54 | 4554 | 108892 | 710812 | 62664764 |
Malignant neoplasm progression | 2393.09 | 13.54 | 1606 | 111840 | 80515 | 63295061 |
Metastases to liver | 1636.21 | 13.54 | 813 | 112633 | 22826 | 63352750 |
Metastases to bone | 1390.06 | 13.54 | 701 | 112745 | 20318 | 63355258 |
Death | 1261.37 | 13.54 | 2332 | 111114 | 372049 | 63003527 |
Mucosal inflammation | 1124.62 | 13.54 | 815 | 112631 | 46113 | 63329463 |
Metastases to central nervous system | 854.34 | 13.54 | 433 | 113013 | 12672 | 63362904 |
Metastases to lung | 815.82 | 13.54 | 416 | 113030 | 12334 | 63363242 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Palmar-plantar erythrodysaesthesia syndrome | 2434.82 | 14.46 | 929 | 52707 | 15866 | 34887429 |
Diarrhoea | 1383.32 | 14.46 | 2271 | 51365 | 387641 | 34515654 |
Disease progression | 1220.83 | 14.46 | 1134 | 52502 | 106943 | 34796352 |
Death | 589.70 | 14.46 | 1629 | 52007 | 396420 | 34506875 |
Arteriospasm coronary | 485.22 | 14.46 | 186 | 53450 | 3196 | 34900099 |
Neuropathy peripheral | 398.58 | 14.46 | 561 | 53075 | 82702 | 34820593 |
Mucosal inflammation | 388.22 | 14.46 | 381 | 53255 | 38241 | 34865054 |
Vomiting | 260.38 | 14.46 | 902 | 52734 | 246719 | 34656576 |
Stomatitis | 256.36 | 14.46 | 321 | 53315 | 42193 | 34861102 |
Dehydration | 255.22 | 14.46 | 594 | 53042 | 129375 | 34773920 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Palmar-plantar erythrodysaesthesia syndrome | 7642.36 | 12.86 | 2609 | 124613 | 30525 | 79586641 |
Disease progression | 3274.06 | 12.86 | 2551 | 124671 | 181811 | 79435355 |
Diarrhoea | 2852.81 | 12.86 | 5037 | 122185 | 875452 | 78741714 |
Malignant neoplasm progression | 1258.15 | 12.86 | 1305 | 125917 | 134685 | 79482481 |
Mucosal inflammation | 1132.18 | 12.86 | 949 | 126273 | 74631 | 79542535 |
Metastases to liver | 1055.66 | 12.86 | 622 | 126600 | 27692 | 79589474 |
Neuropathy peripheral | 884.76 | 12.86 | 1108 | 126114 | 140197 | 79476969 |
Metastases to bone | 818.27 | 12.86 | 501 | 126721 | 23926 | 79593240 |
Arteriospasm coronary | 757.70 | 12.86 | 314 | 126908 | 6402 | 79610764 |
Metastases to lung | 703.26 | 12.86 | 409 | 126813 | 17754 | 79599412 |
None
Source | Code | Description |
---|---|---|
ATC | L01BC06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Pyrimidine analogues |
CHEBI has role | CHEBI:35221 | antimetabolite |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50266 | Prodrugs |
FDA EPC | N0000175595 | Nucleoside Metabolic Inhibitor |
FDA MoA | N0000000233 | Nucleic Acid Synthesis Inhibitors |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000964 | Antimetabolites, Antineoplastic |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D009676 | Noxae |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Metastasis from malignant tumor of colon | indication | 314998002 | |
Malignant tumor of stomach | indication | 363349007 | DOID:10534 |
Metastatic Breast Carcinoma | indication | ||
Lymph Node Positive Colorectal Carcinoma | indication | ||
Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
Adenocarcinoma of pancreas | off-label use | 700423003 | DOID:4074 |
Pancreatic Neuroendocrine Tumor | off-label use | 717919005 | |
Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Infectious disease | contraindication | 40733004 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.3 | acidic |
pKa2 | 12.91 | acidic |
pKa3 | 13.46 | acidic |
pKa4 | 0.75 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Thymidylate synthase | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
007533 | NDDF |
108761006 | SNOMEDCT_US |
11693 | MMSL |
194000 | RXNORM |
210675 | MMSL |
386906001 | SNOMEDCT_US |
4021099 | VUID |
4021099 | VANDF |
4344 | MMSL |
60953 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0271 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0271 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0271 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0271 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0272 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0272 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0272 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0272 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 31 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7473 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 29 sections |
Capecitabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7473 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 29 sections |